Foreword

Dear Alcyone shareholders, dear relations,

It is with great pleasure that I write this foreword by Alcyone. Alcyone is a growing listed company with two activities: Taygeta (consultants) and Sterope (healthcare professionals).

Due to the appointment on December 20, 2023, I have only been a director of Alcyone for 11 days in the past financial year, and that includes public holidays (Christmas and New Year's Eve) and weekend days. For the other 354 days, the director's gavel was in the hands of Jimi Hendrix, who served the company as a director for four years. He led Alcyone – then called Taygeta – through a difficult phase and made an important contribution to the company's current good health. From this place a heartfelt word of thanks to him.

With the acquisition of the majority stake in Sterope in January 2023, Alcyone has been put on a firmer footing. A second leg to stand on. It is gratifying to see that this already had an effect in 2023. Taygeta had a slightly more difficult time – partly due to the shortage in the labour market. Sterope's strong growth more than compensated for this decline.

Today's Alcyone is bigger, more profitable and more promising than it was at the end of 2022. And there's more to come. It is considered that Alcyone will acquire Kitalpha (consultants for the utility sector) in 2024. And Alcyone is emphatically open to further reinforcements from Taygeta and Sterope.

A healthy, growing organization that offers real added value for its customers. This applies to Alcyone and its subsidiaries. I hope you enjoy reading our annual report and hope that you – as a committed shareholder or relation – will join us on the growth path. On behalf of the Board of Directors,

Peter Banks
Chairman